[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Pages 44270-44271]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-18490]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive
[[Page 44271]]
Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/
496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
Therapeutics for the Treatment and Prevention of Atherosclerosis and
Cardiovascular Disease
Description of Invention: This technology consists of peptides and
peptide-analogues that enhance clearance of excess cholesterol in cells
and do not exhibit the cytotoxicity that has hampered development of
similar potential therapeutics.
Briefly, apolipoprotein A-1 (ApoA-1) promotes cholesterol efflux
from cells and its concentration is inversely correlated with
atherosclerotic events. The isolated peptidic component of ApoA-1 that
acts within the cholesterol secretion pathway is therapeutic towards
atherosclerosis but exhibits cytotoxic effects. In contrast, our
inventors have derivatized that ApoA-1 peptide which is both less
cytotoxic and more active than the underivatized component in initial
studies. This potential therapeutic is similar to high density
lipoprotein (HDL) therapy and may complement statin-mediated reduction
of pro-atherogenic lipoproteins.
Potential Applications:
Treatment and prevention of atherosclerosis
Treatment and prevention of cardiovascular disease,
coronary artery disease, heart attack, stroke, and inflammation
Therapeutic or preventative coating for a heart or
vascular implant
Alternative to HDL therapy
Potential Advantages:
Enhanced cytotoxicity profile
Enhanced hydrophilicity profile
Complements statin-based therapies
Oral delivery approaches in development
Development Status: Early stage with in vitro proof of concept
data.
Market: The CDC indicates that heart attacks account for 26% of
deaths in the United States of which atherosclerosis is a significant
contributing factor or cause. Global sales for cardiovascular
therapeutics are expected to exceed $50b in 2010.
Inventors: Amar A. Sethi (NHLBI) et al.
Patent Status: U.S. Provisional Application No. 61/265,291 filed 30
Nov 2009 (HHS Reference No. E-047-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521;
[email protected].
Use of Immunosuppressive Agents for Treatment of Age-related Macular
Degeneration (AMD) and Diabetic Retinopathy
Description of Invention: AMD belongs to a group of disorders in
which the immune system may play an important role. This invention
discloses that patients with AMD gain additional therapeutic benefit
from combination treatment of immunosuppressive agents and standard-of-
care in comparison to standard-of-care alone. This invention slows the
progression of choroidal neovascularization (CNV) and may have
implications for related pathologies, including diabetic retinopathy.
Clinical data from a small, randomized pilot clinical trial are
available.
Applications:
A method of treatment for AMD.
A method of treatment for diabetic retinopathy.
A method of treatment for diseases associated with CNV.
Advantages:
Likely to be synergistic with existing therapeutics.
May enable repurposing of some exiting immunosuppressive
agents.
Development Status: In clinical trials.
Market: An estimated three million individuals in the United States
will have an advanced form of AMD by 2020 (Klein R et al. The
epidemiology of age-related macular degeneration. Am J Ophthalmol.
2004;137(3):486-95).
Inventors: Robert B. Nussenblatt and Frederick L. Ferris (NEI).
Publication: In preparation.
Patent Status: U.S. Provisional Application No. 61/254,439 filed 23
Oct 2009 (HHS Reference No. E-198-2008/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Norbert Pontzer, J.D., Ph.D.; 301-435-5502;
[email protected].
Collaborative Research Opportunity: The National Eye Institute,
Laboratory of Immunology, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the use of immunosuppressive agents
in the treatment of age related macular degeneration. This is in light
of new findings that immune mechanisms appear to be central to the
expression of the clinical disease we know as AMD. Please contact Alan
Hubbs, Ph.D. at 301-594-4263 or [email protected] for more
information.
Dated: July 22, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-18490 Filed 7-27-10; 8:45 am]
BILLING CODE 4140-01-P